Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

E-067

Supelco

Ethosuximide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C7H11NO2
CAS Number:
77-67-8
Molecular Weight:
141.17
EC Number:
200-659-6
UNSPSC Code:
41116107

grade

certified reference material

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

format

single component solution

storage temp.

−20°C

SMILES string

CCC1(C)CC(=O)NC1=O

InChI

1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

InChI key

HAPOVYFOVVWLRS-UHFFFAOYSA-N

Gene Information

human ... CACNA1G(8913) , CACNA1H(8912) , CACNA1I(8911)

General description

Ethosuximide is an anticonvulsant specifically used to treat absence seizures. This Snap-N-Spike® Reference Solution is suitable for LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

B-006

Butalbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

S-002

Secobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-008

Phenobarbital solution, 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-020

Amobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-024

Butabarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-041

Barbiturate Mix-5 solution, 250 μg/mL each component in methanol, ampule of 1.0 mL, certified reference material, Cerilliant®

H-013

Hexobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-010

Pentobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-075

Primidone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

EU REACH Annex XVII (Restriction List)

CAS No.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Joseph Chien
Epilepsy & behavior : E&B, 21(4), 483-485 (2011-06-22)
Psychosis and suicidal ideation have been reported as side effects of ethosuximide treatment, but previous reports seldom place these symptoms in the context of mania. Given the recent renewed interest in ethosuximide as first-line therapy in children and adolescents, it
V Vidal et al.
Neuroscience, 220, 158-168 (2012-06-26)
The Ts65Dn (TS) mouse model of Down syndrome (DS) displays a number of behavioral, neuromorphological and neurochemical phenotypes of the syndrome. Altered GABAergic transmission appears to contribute to the mechanisms responsible for the cognitive impairments in TS mice. Increased functional
Stuart D Greenhill et al.
Neuropharmacology, 62(2), 807-814 (2011-09-29)
Ethosuximide is the drug of choice for treating generalized absence seizures, but its mechanism of action is still a matter of debate. It has long been thought to act by disrupting a thalamic focus via blockade of T-type channels and
Tracy A Glauser et al.
Epilepsia, 54(1), 141-155 (2012-11-22)
Determine the optimal initial monotherapy for children with newly diagnosed childhood absence epilepsy (CAE) based on 12 months of double-blind therapy. A double-blind, randomized controlled clinical trial compared the efficacy, tolerability, and neuropsychological effects of ethosuximide, valproic acid, and lamotrigine
Chinekwu Anyanwu et al.
Journal of child neurology, 28(1), 111-114 (2012-04-03)
Coexistence of 2 idiopathic epilepsy syndromes (ie, childhood absence and Rolandic epilepsy), as evidenced by electroencephalographic (EEG) findings with or without clinical features of the 2 conditions, is uncommon and remains controversial. Few case reports support this coexistence either as
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service